Literature DB >> 12633786

Effect of nitric oxide donor nitroglycerin on bone mineral density in a rat model of estrogen deficiency-induced osteopenia.

M Hukkanen1, L A M Platts, T Lawes, S I Girgis, Y T Konttinen, A E Goodship, I MacIntyre, Julia M Polak.   

Abstract

Nitric oxide (NO) may modulate estrogen's anabolic effects on bone homeostasis by restraining osteoclast-mediated bone resorption and stimulation of osteoblast activity. Accordingly, NO donated by organic nitrates, including nitroglycerin, is thought to protect against bone loss associated with estrogen deficiency. In this study, we have explored this phenomenon. Thirty-two 12-week-old female Wistar rats were divided into four groups prior to bilateral ovariectomy or a sham operation. The ovariectomised rats received (1). vehicle control (OVX control), (2). 17-beta-estradiol (OVX+E2), or (3). transdermal nitroglycerin (OVX+NG) for 4 weeks. Femoral and tibial bone mineral density (BMD), serum alkaline phosphatase and urine deoxypyridinoline and NO metabolites were analysed at the end of the study period together with failure torque and torsional rigidity of the tibiae and cellular localisation of the NO-synthase (NOS) isoforms. In OVX+E2 group, proximal and distal femoral and proximal tibial BMD exceeded that of the Sham controls. Nitroglycerin prevented BMD loss at these three sites at levels comparable to that of the Sham controls. Deoxypyridinoline excretion did not change except in the OVX-E2 group that showed an expected reduction when compared to the Sham and OVX controls. There were no treatment-related differences in total alkaline phosphatase or urinary NO metabolites. Tibial failure torque was comparable between the groups but both OVX+E2 and OVX+NG groups showed decreased torsional rigidity compared with the OVX controls. Endothelial and inducible NOS were found in osteoblast-like cells associated with calcifying cartilage spicules in the distal femoral metaphysis. These data confirm previous findings and show that nitroglycerin counteracts the estrogen deficiency-induced osteopenia in the ovariectomised rat model. Organic nitrates may thus be beneficial in conditions where bone turnover is compromised such as in osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12633786     DOI: 10.1016/s8756-3282(02)00955-9

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  13 in total

Review 1.  Local delivery of nitric oxide: targeted delivery of therapeutics to bone and connective tissues.

Authors:  Scott P Nichols; Wesley L Storm; Ahyeon Koh; Mark H Schoenfisch
Journal:  Adv Drug Deliv Rev       Date:  2012-03-10       Impact factor: 15.470

2.  A Novel, Direct NO Donor Regulates Osteoblast and Osteoclast Functions and Increases Bone Mass in Ovariectomized Mice.

Authors:  Hema Kalyanaraman; Ghania Ramdani; Jisha Joshua; Nadine Schall; Gerry R Boss; Esther Cory; Robert L Sah; Darren E Casteel; Renate B Pilz
Journal:  J Bone Miner Res       Date:  2016-09-07       Impact factor: 6.741

3.  Nitric oxide modulates bone anabolism through regulation of osteoblast glycolysis and differentiation.

Authors:  Zixue Jin; Jordan Kho; Brian Dawson; Ming-Ming Jiang; Yuqing Chen; Saima Ali; Lindsay C Burrage; Monica Grover; Donna J Palmer; Dustin L Turner; Philip Ng; Sandesh Cs Nagamani; Brendan Lee
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

Review 4.  Antihypertensive medications, bone mineral density, and fractures: a review of old cardiac drugs that provides new insights into osteoporosis.

Authors:  Mahua Ghosh; Sumit R Majumdar
Journal:  Endocrine       Date:  2014-02-07       Impact factor: 3.633

5.  Pro-survival effects of 17β-estradiol on osteocytes are mediated by nitric oxide/cGMP via differential actions of cGMP-dependent protein kinases I and II.

Authors:  Nisha Marathe; Hema Rangaswami; Shunhui Zhuang; Gerry R Boss; Renate B Pilz
Journal:  J Biol Chem       Date:  2011-11-22       Impact factor: 5.157

6.  Soluble guanylate cyclase as a novel treatment target for osteoporosis.

Authors:  Jisha Joshua; Gerburg K Schwaerzer; Hema Kalyanaraman; Esther Cory; Robert L Sah; Mofei Li; Florin Vaida; Gerry R Boss; Renate B Pilz
Journal:  Endocrinology       Date:  2014-09-04       Impact factor: 4.736

7.  Effectiveness of extracorporeal shock wave therapy in bone marrow edema syndrome of the hip.

Authors:  Cristina d'Agostino; Pietro Romeo; Vito Lavanga; Salvatore Pisani; Valerio Sansone
Journal:  Rheumatol Int       Date:  2014-11       Impact factor: 2.631

Review 8.  Organic nitrate metabolism and action: toward a unifying hypothesis and the future-a dedication to Professor Leslie Z. Benet.

Authors:  Nathaniel A Page; Ho-Leung Fung
Journal:  J Pharm Sci       Date:  2013-05-13       Impact factor: 3.534

9.  Hydrogen water consumption prevents osteopenia in ovariectomized rats.

Authors:  Ji-Dong Guo; Li Li; Ya-Min Shi; Hua-Dong Wang; Shu-Xun Hou
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

10.  YC-1 alleviates bone loss in ovariectomized rats by inhibiting bone resorption and inducing extrinsic apoptosis in osteoclasts.

Authors:  Jin-Wen Wang; Chin-Bin Yeh; Shao-Jiun Chou; Kuo-Cheng Lu; Tzu-Hui Chu; Wei-Yu Chen; Jui-Lin Chien; Mao-Hsiung Yen; Tien-Hua Chen; Jia-Fwu Shyu
Journal:  J Bone Miner Metab       Date:  2017-10-05       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.